AR056883A1 - Derivados de 7-azaindol-2 carboxamida, un proceso para la preparacion de los mismos, composiciones farmaceuticas que los contienen y su uso en la fabricacion de un medicamento para el tratamiento de enfermedades asociadas con la modulacion de receptores de h3 - Google Patents
Derivados de 7-azaindol-2 carboxamida, un proceso para la preparacion de los mismos, composiciones farmaceuticas que los contienen y su uso en la fabricacion de un medicamento para el tratamiento de enfermedades asociadas con la modulacion de receptores de h3Info
- Publication number
- AR056883A1 AR056883A1 ARP060105035A ARP060105035A AR056883A1 AR 056883 A1 AR056883 A1 AR 056883A1 AR P060105035 A ARP060105035 A AR P060105035A AR P060105035 A ARP060105035 A AR P060105035A AR 056883 A1 AR056883 A1 AR 056883A1
- Authority
- AR
- Argentina
- Prior art keywords
- substituted
- unsubstituted
- halogen
- alkyl
- lower alkyl
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- CZXPBOPRQAPKGX-UHFFFAOYSA-N 1h-pyrrolo[2,3-b]pyridine-2-carboxamide Chemical class C1=CN=C2NC(C(=O)N)=CC2=C1 CZXPBOPRQAPKGX-UHFFFAOYSA-N 0.000 title 1
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 238000004519 manufacturing process Methods 0.000 title 1
- 229940126601 medicinal product Drugs 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 abstract 22
- 125000002768 hydroxyalkyl group Chemical group 0.000 abstract 13
- 229910052736 halogen Inorganic materials 0.000 abstract 12
- 150000002367 halogens Chemical class 0.000 abstract 12
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 10
- 125000003545 alkoxy group Chemical group 0.000 abstract 9
- 125000004438 haloalkoxy group Chemical group 0.000 abstract 5
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 abstract 4
- 125000000623 heterocyclic group Chemical group 0.000 abstract 4
- 229910052739 hydrogen Inorganic materials 0.000 abstract 4
- 239000001257 hydrogen Substances 0.000 abstract 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 4
- 125000003884 phenylalkyl group Chemical group 0.000 abstract 4
- 125000004183 alkoxy alkyl group Chemical group 0.000 abstract 3
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 3
- 125000001072 heteroaryl group Chemical group 0.000 abstract 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 2
- 125000003342 alkenyl group Chemical group 0.000 abstract 2
- 125000004686 alkyl sulfanyl alkyl group Chemical group 0.000 abstract 2
- 125000000304 alkynyl group Chemical group 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 125000004985 dialkyl amino alkyl group Chemical group 0.000 abstract 2
- 125000001188 haloalkyl group Chemical group 0.000 abstract 2
- 125000004446 heteroarylalkyl group Chemical group 0.000 abstract 2
- 125000004415 heterocyclylalkyl group Chemical group 0.000 abstract 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 2
- 229910052757 nitrogen Inorganic materials 0.000 abstract 2
- 229910052760 oxygen Inorganic materials 0.000 abstract 2
- 229920006395 saturated elastomer Polymers 0.000 abstract 2
- 229910052717 sulfur Inorganic materials 0.000 abstract 2
- 102000004384 Histamine H3 receptors Human genes 0.000 abstract 1
- 108090000981 Histamine H3 receptors Proteins 0.000 abstract 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 abstract 1
- 125000004390 alkyl sulfonyl group Chemical group 0.000 abstract 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 abstract 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 abstract 1
- 125000001589 carboacyl group Chemical group 0.000 abstract 1
- 125000004966 cyanoalkyl group Chemical group 0.000 abstract 1
- 125000004663 dialkyl amino group Chemical group 0.000 abstract 1
- 230000006806 disease prevention Effects 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 125000005842 heteroatom Chemical group 0.000 abstract 1
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
- 125000004043 oxo group Chemical group O=* 0.000 abstract 1
- 239000001301 oxygen Substances 0.000 abstract 1
- 125000003170 phenylsulfonyl group Chemical group C1(=CC=CC=C1)S(=O)(=O)* 0.000 abstract 1
- 125000004076 pyridyl group Chemical group 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 abstract 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 abstract 1
- 239000011593 sulfur Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4453—Non condensed piperidines, e.g. piperocaine only substituted in position 1, e.g. propipocaine, diperodon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4462—Non condensed piperidines, e.g. piperocaine only substituted in position 3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/04—Drugs for disorders of the respiratory system for throat disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Pulmonology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Addiction (AREA)
- Epidemiology (AREA)
- Otolaryngology (AREA)
- Child & Adolescent Psychology (AREA)
- Rheumatology (AREA)
- Psychology (AREA)
- Anesthesiology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Los compuestos son utiles para el tratamiento y/o prevencion de enfermedades asociada con la modulacion de receptores de H3, siendo utilizados en medicamentos y en composiciones farmacéuticas que los contienen. También se provee un método para su preparacion. Reivindicacion 1: Compuestos de la formula general (1), en la que R1 se elige entre el grupo que consiste de alquilo inferior, alquenilo inferior, alquinilo inferior, cicloalquilo, cicloalquilalquilo inferior, hidroxialquilo inferior, alcoxialquilo inferior, alquilsulfanilalquilo inferior, dialquilaminoalquilo inferior, dialquilcarbamoilalquilo inferior, fenilo sin sustituir o sustituido con uno o dos grupos elegidos con independencia entre sí entre alquilo inferior, halogenoalcoxi inferior e hidroxialquilo inferior, fenilalquilo inferior, cuyo anillo fenilo puede estar sin sustituir o sustituido con uno o dos grupos elegidos con independencia entre sí entre alquilo inferior, halogeno, alcoxi inferior e hidroxialquilo inferior, heteroarilalquilo inferior, cuyo anillo heteroarilo puede estar sin sustituir o sustituido con uno o dos grupos elegidos con independencia entre si entre alquilo inferior, halogeno, alcoxi inferior e hidroxialquilo inferior y heterociclilalquilo inferior, cuyo anillo heterociclilo puede estar sin sustituir o sustituido con uno o dos grupos alquilo inferior; R2 se elige entre el grupo que consiste de hidrogeno, alquilo inferior, alquenilo inferior, alquinilo inferior, cicloalquilo, cicloalquilalquilo inferior, hidroxialquilo inferior, alcoxialquilo inferior, alquilsulfanilalquilo inferior, dialquilaminoalquilo inferior, dialquilcarbamoilalquilo inferior, fenilo sin sustituir o sustituido con uno o dos grupos elegidos con independencia entre si entre alquilo inferior, halogenoalcoxi inferior e hidroxialquilo inferior, fenilalquilo inferior, cuyo anillo fenilo puede estar sin sustituir o sustituido con uno o dos grupos elegidos con independencia entre sí entre alquilo inferior, halogeno, alcoxi inferior e hidroxialquilo inferior, heteroarilalquilo inferior, cuyo anillo heteroarilo puede estar sin sustituir o sustituido con uno o dos grupos elegidos con independencia entre sí. entre alquilo inferior, halogeno, alcoxi inferior e hidroxialquilo inferior, y heterociclilalquilo inferior, cuyo anillo heterociclilo puede estar sin sustituir o sustituido con uno o dos grupos alquilo inferior; o R1 y R2 junto con el átomo de nitrogeno, al que están unidos, forman un anillo heterocíclico de 4, 5, 6 o 7 eslabones, saturado o parcialmente insaturado, que contiene opcionalmente otro heteroátomo elegido entre nitrogeno, oxígeno o azufre, un grupo sulfinilo o un grupo sulfonilo, dicho anillo heterocíclico saturado o parcialmente insaturado está sin sustituir o sustituido con uno, dos o tres grupos elegidos con independencia entre sí entre alquilo inferior, halogeno, halogenoalquilo, hidroxi, hidroxialquilo inferior, alcoxi inferior, oxo, fenilo, bencilo, piridilo y carbamoilo, o está condensado con un anillo fenilo, dicho anillo fenilo está sin sustituir o sustituido con uno, dos o tres grupos elegidos con independencia entre sí entre alquilo inferior, alcoxi inferior y halogeno; R3 se elige entre el grupo que consiste de hidrogeno, alquilo inferior, hidroxialquilo inferior, alcoxialquilo inferior, halogenoalquilo inferior, cicloalquilalquilo inferior, alcanoílo inferior, cianoalquilo inferior, alquilsulfonilo inferior, fenilsulfonilo, cuyo anillo fenilo puede estar sin sustituir o sustituido con uno o dos grupos elegidos con independencia entre sí entre alquilo inferior, halogeno, alcoxi inferior, halogenoalcoxi. inferior e hidroxialquilo inferior; fenilo sin sustituir o sustituido con uno o dos grupos elegidos con independencia entre sí entre alquilo inferior, halogeno, alcoxi inferior, halogenoalcoxi inferior e hidroxialquilo inferior; fenilalquilo inferior, cuyo anillo fenilo puede estar sin sustituir o sustituido con uno o dos grupos elegidos con independencia entre sí entre alquilo inferior, halogeno, alcoxi inferior, halogenoalcoxi inferior e hidroxialquilo inferior; y heteroarilo sin sustituir o sustituido con uno o dos grupos elegidos con independencia entre sí entre alquilo inferior o halogeno; R4 es hidrogeno o halogeno; R5 es un grupo elegido entre las formulas (2) a (5), en las que m es el numero 0, 1 o 2; n es el numero 0, 1 o 2; X se elige entre CR13R13', O y S; R6, R6', R7, R7', R8, R8', R13 y R13' con independencia entre sí, se eligen entre el grupo que consiste de hidrogeno, alquilo inferior, hidroxi, halogeno y dialquilamino, o R7 y R13 juntos forman un doble enlace; p es el numero 0, 1 o 2; R9 se elige entre alquilo inferior, cicloalquilo, cicloalquilalquilo inferior y fenilalquilo inferior; q es el numero 0, 1 o 2; R10 es alquilo inferior; R11 es alquilo inferior; R12 es alquilo inferior; y las sales farmacéuticamente aceptables de los mismos.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP05110949 | 2005-11-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR056883A1 true AR056883A1 (es) | 2007-10-31 |
Family
ID=37903781
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP060105035A AR056883A1 (es) | 2005-11-18 | 2006-11-16 | Derivados de 7-azaindol-2 carboxamida, un proceso para la preparacion de los mismos, composiciones farmaceuticas que los contienen y su uso en la fabricacion de un medicamento para el tratamiento de enfermedades asociadas con la modulacion de receptores de h3 |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US7622466B2 (es) |
| EP (1) | EP1966199B1 (es) |
| JP (1) | JP2009515926A (es) |
| KR (1) | KR101007489B1 (es) |
| CN (1) | CN101312969A (es) |
| AR (1) | AR056883A1 (es) |
| AT (1) | ATE485294T1 (es) |
| AU (1) | AU2006314649A1 (es) |
| BR (1) | BRPI0618692A2 (es) |
| CA (1) | CA2629232A1 (es) |
| DE (1) | DE602006017741D1 (es) |
| ES (1) | ES2351940T3 (es) |
| NO (1) | NO20082096L (es) |
| RU (1) | RU2417226C2 (es) |
| TW (1) | TWI325425B (es) |
| WO (1) | WO2007057329A1 (es) |
| ZA (1) | ZA200804257B (es) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2079694B1 (en) | 2006-12-28 | 2017-03-01 | Rigel Pharmaceuticals, Inc. | N-substituted-heterocycloalkyloxybenzamide compounds and methods of use |
| EP2025674A1 (de) | 2007-08-15 | 2009-02-18 | sanofi-aventis | Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| ES2567283T3 (es) | 2008-06-03 | 2016-04-21 | Intermune, Inc. | Compuestos y métodos para tratar trastornos inflamatorios y fibróticos |
| EP2683705B1 (de) | 2011-03-08 | 2015-04-22 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| US8828995B2 (en) | 2011-03-08 | 2014-09-09 | Sanofi | Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof |
| EP2683699B1 (de) | 2011-03-08 | 2015-06-24 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| EP2766349B1 (de) | 2011-03-08 | 2016-06-01 | Sanofi | Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
| EP2683700B1 (de) | 2011-03-08 | 2015-02-18 | Sanofi | Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| MX2015001897A (es) | 2012-08-17 | 2015-05-11 | Bayer Cropscience Ag | Azaindolcarboxamidas y azaindoltiocarboxamidas como insecticidas y acaricidas. |
| AR092742A1 (es) | 2012-10-02 | 2015-04-29 | Intermune Inc | Piridinonas antifibroticas |
| CA2943363A1 (en) | 2014-04-02 | 2015-10-08 | Intermune, Inc. | Anti-fibrotic pyridinones |
| TWI674260B (zh) | 2017-02-01 | 2019-10-11 | 德商菲尼克斯製藥股份有限公司 | 芳基烴受體(AhR)調節劑化合物 |
| TWI752155B (zh) | 2017-02-01 | 2022-01-11 | 德商菲尼克斯製藥股份有限公司 | 芳香烴受體(AhR)調節劑化合物 |
| CN113164487B (zh) | 2018-10-12 | 2024-11-26 | 内布拉斯加大学董事委员会 | 磷酸二酯酶抑制剂 |
| WO2020168068A1 (en) * | 2019-02-13 | 2020-08-20 | The University Of Vermont And State Agricultural College | Small molecule antagonist to pacap receptor and uses thereof |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0572863A1 (de) * | 1992-06-05 | 1993-12-08 | F. Hoffmann-La Roche Ag | ZNS Pyrazinoindole |
| MX9700693A (es) | 1994-07-26 | 1997-04-30 | Pfizer | Derivados del 4-indol. |
| US20020061892A1 (en) * | 2000-02-22 | 2002-05-23 | Tao Wang | Antiviral azaindole derivatives |
| GB0106177D0 (en) * | 2001-03-13 | 2001-05-02 | Hoffmann La Roche | Piperazine derivatives |
| GB0202015D0 (en) * | 2002-01-29 | 2002-03-13 | Hoffmann La Roche | Piperazine Derivatives |
| IL165863A0 (en) * | 2002-06-24 | 2006-01-15 | Schering Corp | Indole derivatives useful as histamine H3 antagonists |
| US20060167046A1 (en) * | 2002-09-18 | 2006-07-27 | Eli Lilly And Company Patent Division | Histamine h3 receptor antagonists, preparation and therapeutic uses |
| GB0224084D0 (en) * | 2002-10-16 | 2002-11-27 | Glaxo Group Ltd | Novel compounds |
| MXPA05006567A (es) * | 2002-12-20 | 2005-08-16 | Glaxo Group Ltd | Derivados de benzazepina para el tratamiento de trastornos neurologicos. |
| FI20030556A0 (fi) * | 2003-04-11 | 2003-04-11 | Abb Oy | Menetelmä ja laitteisto laivan ohjaamiseksi |
| US20040224952A1 (en) * | 2003-05-07 | 2004-11-11 | Cowart Marlon D. | Fused bicyclic-substituted amines as histamine-3 receptor ligands |
| EP1479680A1 (en) * | 2003-05-19 | 2004-11-24 | Aventis Pharma Deutschland GmbH | Azaindole derivatives as Factor Xa inhibitors |
| GB0314967D0 (en) * | 2003-06-26 | 2003-07-30 | Hoffmann La Roche | Piperazine derivatives |
| ES2337376T3 (es) | 2004-04-01 | 2010-04-23 | Eli Lilly And Company | Agentes receptores de la histamina h3, preparacion y usos terapeuticos. |
-
2006
- 2006-11-08 EP EP06829951A patent/EP1966199B1/en not_active Not-in-force
- 2006-11-08 KR KR1020087011709A patent/KR101007489B1/ko not_active Expired - Fee Related
- 2006-11-08 RU RU2008123728/04A patent/RU2417226C2/ru not_active IP Right Cessation
- 2006-11-08 DE DE602006017741T patent/DE602006017741D1/de active Active
- 2006-11-08 ES ES06829951T patent/ES2351940T3/es active Active
- 2006-11-08 AU AU2006314649A patent/AU2006314649A1/en not_active Abandoned
- 2006-11-08 CN CNA2006800424869A patent/CN101312969A/zh active Pending
- 2006-11-08 CA CA002629232A patent/CA2629232A1/en not_active Abandoned
- 2006-11-08 WO PCT/EP2006/068206 patent/WO2007057329A1/en not_active Ceased
- 2006-11-08 BR BRPI0618692-0A patent/BRPI0618692A2/pt not_active IP Right Cessation
- 2006-11-08 JP JP2008540579A patent/JP2009515926A/ja active Pending
- 2006-11-08 AT AT06829951T patent/ATE485294T1/de active
- 2006-11-08 US US12/093,669 patent/US7622466B2/en not_active Expired - Fee Related
- 2006-11-15 TW TW095142180A patent/TWI325425B/zh not_active IP Right Cessation
- 2006-11-16 AR ARP060105035A patent/AR056883A1/es not_active Application Discontinuation
-
2008
- 2008-05-06 NO NO20082096A patent/NO20082096L/no not_active Application Discontinuation
- 2008-05-16 ZA ZA200804257A patent/ZA200804257B/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2009515926A (ja) | 2009-04-16 |
| US20090005379A1 (en) | 2009-01-01 |
| BRPI0618692A2 (pt) | 2011-09-06 |
| CN101312969A (zh) | 2008-11-26 |
| NO20082096L (no) | 2008-05-29 |
| TW200804374A (en) | 2008-01-16 |
| EP1966199A1 (en) | 2008-09-10 |
| RU2417226C2 (ru) | 2011-04-27 |
| ES2351940T3 (es) | 2011-02-14 |
| DE602006017741D1 (de) | 2010-12-02 |
| ZA200804257B (en) | 2009-04-29 |
| KR20080057349A (ko) | 2008-06-24 |
| CA2629232A1 (en) | 2007-05-24 |
| AU2006314649A1 (en) | 2007-05-24 |
| EP1966199B1 (en) | 2010-10-20 |
| RU2008123728A (ru) | 2009-12-27 |
| WO2007057329A1 (en) | 2007-05-24 |
| KR101007489B1 (ko) | 2011-01-12 |
| US7622466B2 (en) | 2009-11-24 |
| TWI325425B (en) | 2010-06-01 |
| ATE485294T1 (de) | 2010-11-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR049696A1 (es) | Derivados de indol | |
| AR060593A1 (es) | 5-amido-2-carboxiamida-indoles | |
| AR056883A1 (es) | Derivados de 7-azaindol-2 carboxamida, un proceso para la preparacion de los mismos, composiciones farmaceuticas que los contienen y su uso en la fabricacion de un medicamento para el tratamiento de enfermedades asociadas con la modulacion de receptores de h3 | |
| AR057989A1 (es) | Derivados de indol-2-il-amida 1,5-sustituida. procesos de obtencion y composiciones farmaceuticas | |
| AR039127A1 (es) | Compuesto de quinolina, procedimiento para su preparacion, composicion farmaceutica que lo comprende y uso del mismo para la fabricacion de un medicamento | |
| CO5570668A2 (es) | Derivados triciclicos sustituidos de himbacina que son antagonistas del receptor de trombina y composiciones farmaceuticas que los contienen | |
| AR038249A1 (es) | Compuestos derivados de quinolina, procedimientos para su preparacion, composiciones farmaceuticas que los comprenden, y uso de dichos compuestos derivados en la preparacion de un medicamento | |
| ECSP045368A (es) | "antagonistas de los receptores de trombina" | |
| PE20001464A1 (es) | Derivados quinolin-2-ona sustituidos con heteroarilo utiles como agentes anticancerigenos | |
| AR069772A1 (es) | Derivados heterociclicos, una composicion farmaceutica y un juego que los comprenden y su uso en la preparacion de un medicamento para el tratamiento de una infeccion parasitaria. | |
| AR059094A1 (es) | Derivados de ciclohexil - sulfonamida | |
| AR066460A2 (es) | Compuestos derivados de fenil-piperazina, fenil-piperidina y fenil-tetrahidropiridina como inhibidores de la reabsorcion de la serotonina, una composicion farmaceutica y utilizacion de los mismos para la preparacion de medicamentos | |
| AR061486A1 (es) | Derivados de 2-pirazinacarboxamida | |
| AR046779A1 (es) | Derivados de pirazol, metodos para su preparacion y usos de los mismos en la fabricacion de composiciones farmaceuticas y medicamentos que los contienen con actividad inhibitoria de trk para el tratamiento o profilaxis del cancer. | |
| NO20081970L (no) | Sulfonamidderivat med PGD2-reseptorantagonistaktivitet | |
| EA200600811A1 (ru) | НОВЫЕ ПРОИЗВОДНЫЕ ТЕТРАГИДРОСПИРО {ПИПЕРИДИН-2,7'-ПИРРОЛО [3,2-b]ПИРИДИНА} И НОВЫЕ ПРОИЗВОДНЫЕ ИНДОЛА, ПРИМЕНЕНИЕ ДЛЯ ЛЕЧЕНИЯ РАССТРОЙСТВ, СВЯЗАННЫХ С 5-HT-РЕЦЕПТОРОМ | |
| AR031556A1 (es) | Derivados de 3-(diarilmetilen)-8-azabiciclo[3.2.1] octano y composiciones farmaceuticas que los comprenden | |
| AR060658A1 (es) | Derivados de diceto-piperazina y piperidina como agentes antivirales | |
| AR057104A1 (es) | Diaminopirimidinas como moduladores de p2 x3 y p2x2 /3 y composicion farmaceutica | |
| ECSP045367A (es) | "derivados de bencimidazol utiles como antagonistas de histamina h3" | |
| AR036598A1 (es) | Derivados de 4,5-dihidro-1h-pirazol que tienen potente actividad antagonista de cb1 | |
| AR054024A1 (es) | Derivados de piridina -3- carboxamida como agonistas inversos de cb1 | |
| AR047557A1 (es) | Compuestos derivados de piridazina y su uso como agentes terapeuticos | |
| NO20025641D0 (no) | Substituerte 1-aminoalkyl-laktamer og deres anvendelse som muscarin-reseptor-antagonister | |
| EA200801909A1 (ru) | Соединения пиридина для лечения заболеваний, опосредованных действием простагландина |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |